3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
15
Phase 1/2
10
Phase 1
9
Phase 3
3
Phase 2/3
3
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
3
Other hematologic neoplasm
1
Conditions
Lymphoma, Large B-Cell, Diffuse
3
Leukemia, Lymphocytic, Chronic, B-Cell
2
Recurrence
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
Rituximab
8
Cyclophosphamide
7
Etoposide
5
Prednisone
4
Doxorubicin
4
Vincristine
3
Gemcitabine
3
Bendamustine Hydrochloride
3
prednylidene
2
deltacortene
2
Specimen Handling
2
Oxaliplatin
2
Magnetic Resonance Spectroscopy
2
CT-P10
2
Busulfan
2
venetoclax
1
umbralisib
1
ublituximab
1
tebufenozide
1
tafasitamab
1
selinexor
1
huachansu
1
fludarabine phosphate
1
epratuzumab
1
cc-486
1
Whole-Body Irradiation
1
Vindesine
1
VAP-cyclo protocol
1
Thiotepa
1
Tamoxifen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lymphoma, Large B-Cell, Diffuse
×
Bendamustine Hydrochloride
×
Clear all
NCT05139017
2026-05-22
waveLINE-003
Merck Sharp & Dohme LLC
Phase 2/3
Recruiting
290 enrolled
NCT02763319
2025-07-17
B-MIND
Incyte Corporation
Phase 2/3
Completed
453 enrolled
29 charts
NCT02793583
2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3
Terminated
710 enrolled
1 FDA